China Universal Asset Management Co. Ltd. Buys 5,294 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

China Universal Asset Management Co. Ltd. grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 11.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,123 shares of the biotechnology company’s stock after buying an additional 5,294 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in ADMA Biologics were worth $860,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Hollencrest Capital Management acquired a new position in ADMA Biologics in the 3rd quarter worth $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics in the 3rd quarter valued at approximately $31,000. GAMMA Investing LLC boosted its position in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the last quarter. National Bank of Canada FI bought a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $35,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics in the third quarter worth $62,000. Institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ADMA shares. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James raised their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Performance

Shares of ADMA opened at $16.15 on Friday. The company has a market cap of $3.82 billion, a PE ratio of 57.68 and a beta of 0.76. The firm has a 50-day moving average of $18.10 and a 200-day moving average of $17.58. ADMA Biologics, Inc. has a one year low of $5.02 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the previous year, the business earned $0.01 earnings per share. As a group, equities analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.